Mohamed Hebbar

10.3k total citations
151 papers, 4.6k citations indexed

About

Mohamed Hebbar is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mohamed Hebbar has authored 151 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 41 papers in Hepatology and 36 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mohamed Hebbar's work include Colorectal Cancer Treatments and Studies (49 papers), Hepatocellular Carcinoma Treatment and Prognosis (39 papers) and Cancer Treatment and Pharmacology (25 papers). Mohamed Hebbar is often cited by papers focused on Colorectal Cancer Treatments and Studies (49 papers), Hepatocellular Carcinoma Treatment and Prognosis (39 papers) and Cancer Treatment and Pharmacology (25 papers). Mohamed Hebbar collaborates with scholars based in France, United States and Belgium. Mohamed Hebbar's co-authors include Stéphanie Truant, Jean‐Philippe Peyrat, Louis Hornez, B Devulder, François‐René Pruvot, Pierre Fenaux, Emmanuelle Leteurtre, Alain Duhamel, Yves Delneste and É. Hachulla and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Mohamed Hebbar

144 papers receiving 4.5k citations

Peers

Countries citing papers authored by Mohamed Hebbar

Since Specialization

Citations

This map shows the geographic impact of Mohamed Hebbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Hebbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Hebbar more than expected).

Fields of papers citing papers by Mohamed Hebbar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamed Hebbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Hebbar. The network helps show where Mohamed Hebbar may publish in the future.

Co-authorship network of co-authors of Mohamed Hebbar

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamed Hebbar. A scholar is included among the top collaborators of Mohamed Hebbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamed Hebbar. Mohamed Hebbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results 2020 ·Quality of Life Research ·Caroline Mollévi, (unknown), C. Bourgier, Thierry Conroy, Bruno Chauffert, Mohamed Hebbar, William Jacot, Béata Juzyna, Hélène de Forges, Sophie Gourgou, Franck Bonnetain, Célia Touraine, Amélie Anota	10
2	Laparoscopic Partial ALPPS: Much Better Than ALPPS! 2018 ·Annals of Hepatology ·Stéphanie Truant, Mehdi El Amrani, C. Baillet, (unknown), Katia Lécolle, Olivier Ernst, Mohamed Hebbar, D. Huglo, François‐René Pruvot	23
3	Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial 2016 ·PLoS ONE ·Zeinab Hamidou, Benoist Chibaudel, Mohamed Hebbar, (unknown), Thierry André, Christophe Louvet, (unknown), Marie‐Line Garcia‐Larnicol, Aimery de Gramont, Franck Bonnetain	12
4	HER2 based expression subpopulations in TNBC: pathological aspects and clinical significance 2016 ·Annals of Oncology ·(unknown), Christophe Desauw, Mohamed Hebbar	2
5	A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer 2015 ·Annals of Oncology ·G. Deplanque, Martin Demarchi, Mohamed Hebbar, Patrick J. Flynn, Bohuslav Melichar, J. Atkins, Elżbieta Nowara, Lem Moyé, David Piquemal, (unknown), Patrice Dubreuil, Colin D. Mansfield, (unknown), Alain Moussy, Olivier Hermine, Pascal Hammel	78
6	Relevance of the ISGLS Definition of Posthepatectomy Liver Failure in Early Prediction of Poor Outcome After Liver Resection 2014 ·Annals of Surgery ·(unknown), Stéphanie Truant, Alain Duhamel, Carole Langlois, Emmanuel Boleslawski, (unknown), Mohamed Hebbar, François Fourrier, Philippe Mathurin, F.R. Pruvot	58
7	High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer. 2013 ·PubMed ·Mohamed Hebbar, Stéphanie Truant, Christophe Desauw, (unknown), Stéphane Cattan, Guillaume Piessen, François‐René Pruvot	4
8	Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228). 2013 ·Journal of Clinical Oncology ·Françis Lévi, Valérie Boige, Mohamed Hebbar, Denis Smith, Céline Lepère, C. Focan, Rosine Guimbaud, Carlos Carvalho, Salvatore Tumolo, Pasquale F. Innominato, Y. Ajavon, Stéphanie Truant, Denis Castaing, (unknown), F Kunstlinger, Abdoulaye Karaboué, Mohamed Bouchahda, Philippe Rougier, René Adam, Michel Ducreux, (unknown)	1
9	Inhibition of Tissue Factor—Factor VIIa Proteolytic Activity Blunts Hepatic Metastasis in Colorectal Cancer 2008 ·Journal of Surgical Research ·Philippe Zerbib, (unknown), Delphine Corseaux, Frédéric Mouquet, (unknown), Lars C. Petersen, Sophie Susen, Alexandre Ung, Mohamed Hebbar, F.R. Pruvot, (unknown), Brigitte Jude	13
10	Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer 2007 ·Oncology ·Mohamed Hebbar, Frédéric Di Fiore, Thierry Conroy, (unknown), (unknown), Charles Fournier, Renata Péreira, Olivier Bouché, (unknown), (unknown), Jean‐Paul Joly, (unknown), (unknown), Pierre Michel, Antoine Adenis	8
11	Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study 2006 ·Annals of Oncology ·Thierry André, Christophe Tournigand, Laurent Mineur, (unknown), M. Flesch, May Mabro, Mohamed Hebbar, S. P. Vinay, François‐Clément Bidard, Christophe Louvet, Aimery de Gramont	38
12	Association between systemic sclerosis and breast cancer: eight new cases and review of the literature 2004 ·Clinical Rheumatology ·David Launay, Rozenn Le Berre, Pierre‐Yves Hatron, Jean‐Philippe Peyrat, É. Hachulla, B Devulder, Mohamed Hebbar	36
13	Expression of nerve growth factor receptors and their prognostic value in human breast cancer 2001 ·HAL (Le Centre pour la Communication Scientifique Directe) ·Simon Descamps, Valérie Pawlowski, (unknown), (unknown), Mohamed Hebbar, B. Boilly, Hubert Hondermarck, J.P. Peyrat	91
14	Dépistage de l’hypertension artérielle pulmonaire au cours de la sclérodermie systémique : étude d’une cohorte de 67 patients 2001 ·La Revue de Médecine Interne ·David Launay, É. Hachulla, P.Y. Hatron, U. Michon-Pasturel, Mohamed Hebbar, V. Queyrel, L Goullard, Stéphane Robin, Martine Rémy‐Jardin, B Devulder	23
15	Bronchiolite oblitérante avec pneumopathie organisée: une complication rare du syndrome de Gougerot-Sjögren primitif 2000 ·La Revue de Médecine Interne ·M. Lambert, Mohamed Hebbar, N. Viget, P.Y. Hatron, É. Hachulla, B Devulder	12
16	Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. 1998 ·PubMed ·Vincent Blanckaert, Mohamed Hebbar, M M Louchez, M O Vilain, Margaret E. Schelling, J.P. Peyrat	44
17	Age as a prognostic factor in breast cancer. 1998 ·PubMed ·Laurence Vanlemmens, Mohamed Hebbar, (unknown), Jacques Bonneterre	20
18	Corrélations entre expression endothéliale salivaire de la E-sélectine et paramètres cliniques et biologiques au cours de la sclérodermie systémique 1998 ·La Revue de Médecine Interne ·Mohamed Hebbar, Anne Janin, Philippe Lassalle, PY Hatron, É. Hachulla, A B Tonnel, B Devulder	3
19	Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques 1996 ·British Journal of Haematology ·Pierre Morel, Christophe Declercq, Mohamed Hebbar, F Bauters, Pierre Fenaux	38
20	Maladies systémiques au cours des syndromes myélodysplasiques 1995 ·La Revue de Médecine Interne ·Mohamed Hebbar, (unknown), Pierre Fenaux	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact